Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05217576 · ClinicalTrials.gov registry record · NA
NBM-200 Clinical Study in Blood Donation Setting
A NA study of Hemoglobin H, sponsored by OneBlood.
- Completed
- Registry status
- NA
- Development phase
- 387
- Enrollment target
- 3
- Study locations
NCT05217576 is a NA study of Hemoglobin H that has completed, run by OneBlood. The registered enrollment target is 387 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT05217576, a NA study of Hemoglobin H, has completed, sponsored by OneBlood.
- COMPLETED
- Registry status
- NA
- Development phase
- 387 participants
- Enrollment target
- 3
- Study locations
Study Summary
The NBM-200 is a portable Hemoglobin and oximetry monitor, based on occlusion spectroscopy technology, for non-invasive spot checking of hemoglobin (Hb), estimated Hematocrit (Hct), SpO2 and pulse rate. The NBM-200 includes a reusable ring-shaped sensor probe that fits on the patient's finger, and a portable desktop monitor that calculates and displays the measurement result. The sensor probe consists of a multi-wavelength optical measuring system and inflatable cuff employing pneumatic tissue manipulation. Blood flow in the finger can be briefly occluded and the resulting changes in its optical behavior are analyzed to provide accurate measurements of Hb.
Conditions Studied
Interventions
- DEVICE NBM-200
Study Locations (3)
Florida
- Palm Harbor Donor Center - Palm Harbor
- OneBlood St. Pete Main Donor Center - St. Petersburg
- Tampa- Dale Mabry OneBlood Donor Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2018-11-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05217576
The ClinicalTrials.gov registry entry for NCT05217576 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OneBlood, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemoglobin H appearing as the primary indexed condition, and to 1 intervention - of which NBM-200 is the first listed.
NCT05217576 reports 3 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05217576 about?
NCT05217576 is a clinical study titled "NBM-200 Clinical Study in Blood Donation Setting". The NBM-200 is a portable Hemoglobin and oximetry monitor, based on occlusion spectroscopy technology, for non-invasive spot checking of hemoglobin (Hb), estimated Hematocrit (Hct), SpO2 and pulse rate. The NBM-200 includes a reusable ring-shaped sensor probe that fits on the patient's finger, and ...
What is the current status of trial NCT05217576?
This trial is currently completed. It is a NA study. The enrollment target is 387 participants. The study started on 2018-09-21. Estimated completion is 2018-11-02.
What conditions does trial NCT05217576 study?
This clinical trial studies the following conditions: Hemoglobin H.
What interventions are being tested in trial NCT05217576?
The interventions under investigation include: NBM-200 (DEVICE).
Who is sponsoring clinical trial NCT05217576?
This trial is sponsored by OneBlood, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05217576 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.